A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy

Epilepsia

Volumn 49, Issue 10, 2008, Pages 1787-1794

  L grabenstatter, Heidi ^a,b   Dudek, F Edward ^a,c  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Convulsive seizure; Kainic acid; Temporal lobe epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARISBAMATE; KAINIC ACID; SOLUTOL HS 15; TOPIRAMATE; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE; S 2 O CARBAMOYL 1 O CHLOROPHENYL ETHANOL; S-2-O-CARBAMOYL-1-O-CHLOROPHENYL-ETHANOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EPILEPSY; EPILEPTIC STATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CROSSOVER PROCEDURE; DISEASE MODEL; DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TIME; VIDEORECORDING;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; CARBAMATES; CROSS-OVER STUDIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FRUCTOSE; KAINIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; TIME FACTORS; VIDEO RECORDING;

EID: 51449116680     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01657.x     Document Type: Article

References (25)

1. Bauer J, Burr W. (2001) Course of chronic focal epilepsy resistant to anticonvulsant treatment. Seizure 10:239246.
2. Cole AJ. (2004) Guidelines for new epilepsy drugs. New epilepsy drugs are safer and cause fewer adverse effects than their predecessors. But they're not more effective. Health News 10:6-7.
3. Elger CE. (2003) Pharmacoresistance: modern concept and basic data derived from human brain tissue. Epilepsia 44(Suppl. 5):9-15.
4. Francois J, Boehrer A, Nehlig A. (2008) Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the Audiogenic Wistar. Epilepsia 49:393-399.
5. Grabenstatter HL, Ferraro DJ, Williams PA, Chapman PL, Dudek FE. (2005) Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 46:8-14.
6. Grabenstatter HL, Clark S, Dudek FE. (2007) Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. Epilepsia 48:2287-2295.
7. Heinemann U, Draguhn A, Ficker E, Stabel J, Zhang CL. (1994) Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia 35(Suppl. 5):S10-S21.
8. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE. (1998) Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 31:73-84.
9. Kupferberg H. (2001) Animal models used in the screening of antiepileptic drugs. Epilepsia 42(Suppl. 4):7-12.
10. Leite JP, Garcia-Cairasco N, Cavalheiro EA. (2002) New insights from the use of pilocarpine and kainate models. Epilepsy Res 50:93-103.
11. Levy RH, Mattson RH, Meldrum BS, Perucca E. (2002) Antiepileptic drugs. In White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH (Eds) Discovery and preclinical development of antiepileptic drugs. 5th ed. Lippincott, Williams, & Wilkins, Philadelphia, pp. 36-48.
12. Loscher W, Schmidt D. (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145-181.
13. Margerison JH, Corsellis JA. (1966) Epilepsy and the temporal lobes. A clinical, electroencephalographic and neuropathological study of the brain in epilepsy, with particular reference to the temporal lobes. Brain 89:499-530.
14. Novak GP, Kelley M, Sannikos P, Klein B. (2007) Carisbamate (RWJ-333369). Neurotherapeutics 4:106-109.
15. Pitkanen A, Sutula TP. (2002) Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 1:173-181.
16. Racine RJ. (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281-294.
17. Rogawski MA, Loscher W. (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553-564.
18. Schmidt D, Rogawski MA. (2002) New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res 50:71-78.
19. Sisodiya SM. (2003) Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16:197-201.
20. Stables JP, Bertram EH, White HS, Coulter DA, Dichter MA, Jacobs MP, Loscher W, Lowenstein DH, Moshe SL, Noebels JL, Davis M. (2002) Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 43:1410-1420.
21. Stables JP, Bertram E, Dudek FE, Holmes G, Mathern G, Pitkanen A, White HS. (2003) Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 44:1472-1478.
22. White HS. (1997) Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 38(Suppl. 1):S9-S17.
23. White HS. (2003) Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44(Suppl. 7):2-8.
24. White HS, Srivastava A, Klein B, Zhao B, Choi YM, Gordon R, Lee SJ. (2006) The novel investigational neuromodulator RWJ 333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. Epilepsia 47(Suppl 4): 200. (Abstract).
25. Wieser HG. (2004) ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 45:695-714.